Beryllium BioBank: 2. Lymphocyte proliferation testing.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 25099413.
- Also identified by DOI 10.1097/JOM.0000000000000199.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To incrementally improve the use of beryllium lymphocyte proliferation test (LPT) results. Beryllium BioBank data were analyzed for 532 subjects in three groups: beryllium-exposed, sensitized, or chronic beryllium disease. Predictor variables were LPT stimulation index (SI) at the date of the earliest available data and at the study entry date. Cross-sectionally, LPT SI magnitude does not distinguish among the three groups. The likelihood of progression from sensitization to disease is associated with the absolute value of SI, but LPT SI interpreted by traditional cut point criteria was not predictive. Updating the criteria for interpreting beryllium LPT data should be considered. Prediction of progression to chronic beryllium disease may be improved by changing the cut point for interpretation or by using the SI as a continuous variable.
Medical subject headings
- Berylliosis
- Lymphocytes